Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

For the majority of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), clinical diagnosis can be aided by mutational findings in JAK2, CALR or MPL . The JAK2 V617F mutation is found in about half of the cases and has been included as a major criterion for diagnosis in the